财中社2月11日电艾美疫苗（06660）发布公告，近日公司向中国药品监督管理局药品评审中心申报了mRNA带状疱疹疫苗的临床试验。根据公告，公司的mRNA带状疱疹疫苗在临床前动物试验中显示出特异性T细胞免疫、IgG抗体滴度和膜抗原荧光抗体滴度均显著高于市售的重组亚单位对照疫苗。这表明该疫苗在免疫保护方面具有明显优势。
此外，公告中提到，带状疱疹病毒的特殊性使得其在初次感染后终身潜伏，T细胞介导的免疫保护是控制病毒再激活的关键。当前，带状疱疹疫苗在目标人群中的接种率仅为0.1%左右，市场潜力巨大。根据行业顾问的预测，预计到2030年，带状疱疹疫苗在中国的市场规模将达到约200亿元，全球市场规模将达到约239亿美元。若该产品获批上市，将为公司带来可观的业绩增长。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.